Skip to main content
. 2020 Sep 22;9(1):2061–2075. doi: 10.1080/22221751.2020.1821581

Figure 7.

Figure 7.

The effect of miR-142-5p targets, ITGAV and IL6ST, on ZIKV infection. (A, B) A549 cells were transfected with control or ITGAV or AXL-specific siRNA followed by ZIKV infection (PRVABC59) at MOI of 1 for 24 h. The knockdown efficiency of ITGAV or AXL-specific siRNA treatment was measured by qRT-PCR. (B) Expression levels of ZIKV vRNA were measured by qRT-PCR. The results represent mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001, compared with control siRNA-treated cells. (C) A549 cells were transfected with control or IL6ST-specific siRNA followed by ZIKV infection (MR766 or PRVABC59) at MOI of 1 for 24 h. Expression levels of ZIKV NS5, IL6ST and OAS1 were measured by qRT-PCR. Data are representative of three independent experiments (mean ± SD). *p < 0.05, **p < 0.01, and ***p < 0.001, compared with control siRNA-transfected cells. (D) Expression of STAT3, TBK1, and β-actin was determined by Western blotting analysis in cell lysates of mock vs ZIKV-infected cells.